GlassScriptPhysician profile
Leah Grubbs
NPI 1558140202
$1,656.73
in general payments reported to CMS, 2019-2025
20 companies · $836 in 2025
The $836 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $185 · 2024: $635 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $296.25 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $274.79 | 2023-2025 | |
| Novo Nordisk INC | $249.98 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $134.59 | 2023-2024 | Mounjaro, Trulicity, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.14 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $96.46 | 2023-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $78.37 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.94 | 2024-2025 | Jardiance |
| Viatris Specialty LLC | $52.35 | 2025 | Yupelri |
| Globus Medical, INC. | $49.19 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.50 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $45.60 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $34.23 | 2025 | Fanapt |
| Astellas Pharma US INC | $23.32 | 2025 | Veozah |
| Radius Health, INC. | $23.06 | 2024 | Tymlos |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.30 | 2024 | Auvelity |
| Mylan Specialty L.P. | $16.22 | 2024 | Yupelri |
| Electromed, INC. | $16.03 | 2024 | Smartvest |
| Amgen INC. | $14.07 | 2025 | Repatha |
| Phathom Pharmaceuticals, INC. | $11.34 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Grubbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.